蚌埠医学院学报
蚌埠醫學院學報
방부의학원학보
ACTA ACADEMIAE MEDICINAE BENGBU
2014年
5期
593-595,596
,共4页
腹膜炎%安妥沙星%头孢噻肟
腹膜炎%安妥沙星%頭孢噻肟
복막염%안타사성%두포새우
peritonitis%antofloxacin%cefotaxime
目的:观察安妥沙星对社区获得非复杂性肝硬化自发性腹膜炎的疗效和治疗安全性。方法:51例自发性腹膜炎患者均为社区获得、非复杂性肝硬化患者,随机分为观察组24例和对照组27例,其中对照组静脉使用头孢噻肟每次2 g,每天2次,共10 d;观察组口服安妥沙星片,首日1次400 mg,以后9 d每天1次200 mg。结果:观察组口服安妥沙星片10 d后丙氨酸氨基转移酶和总胆红素均较治疗前降低(P<0.05),白蛋白较治疗前升高(P<0.01),而肌酐和凝血酶原时间均无明显变化(P>0.05),QT间期无延长,2组治疗有效率差异无统计学意义(P>0.05)。结论:口服安妥沙星治疗非复杂性肝硬化自发性腹膜炎安全有效。
目的:觀察安妥沙星對社區穫得非複雜性肝硬化自髮性腹膜炎的療效和治療安全性。方法:51例自髮性腹膜炎患者均為社區穫得、非複雜性肝硬化患者,隨機分為觀察組24例和對照組27例,其中對照組靜脈使用頭孢噻肟每次2 g,每天2次,共10 d;觀察組口服安妥沙星片,首日1次400 mg,以後9 d每天1次200 mg。結果:觀察組口服安妥沙星片10 d後丙氨痠氨基轉移酶和總膽紅素均較治療前降低(P<0.05),白蛋白較治療前升高(P<0.01),而肌酐和凝血酶原時間均無明顯變化(P>0.05),QT間期無延長,2組治療有效率差異無統計學意義(P>0.05)。結論:口服安妥沙星治療非複雜性肝硬化自髮性腹膜炎安全有效。
목적:관찰안타사성대사구획득비복잡성간경화자발성복막염적료효화치료안전성。방법:51례자발성복막염환자균위사구획득、비복잡성간경화환자,수궤분위관찰조24례화대조조27례,기중대조조정맥사용두포새우매차2 g,매천2차,공10 d;관찰조구복안타사성편,수일1차400 mg,이후9 d매천1차200 mg。결과:관찰조구복안타사성편10 d후병안산안기전이매화총담홍소균교치료전강저(P<0.05),백단백교치료전승고(P<0.01),이기항화응혈매원시간균무명현변화(P>0.05),QT간기무연장,2조치료유효솔차이무통계학의의(P>0.05)。결론:구복안타사성치료비복잡성간경화자발성복막염안전유효。
Objective:To evaluate the efficacy and safety of antofloxacin in the treatment of community-acquired uncomplicated spontaneous bacterial peritonitis ( SBP) infection. Methods:Fifty-one cirrhotic patients with community-acquired uncomplicated SBP were divided into observation group ( n =24 ) and control group ( n =27 ) . The control group received cefotaxime 2 g intravenously 2 times a day for 10 days and the observation group were given antofloxacin 400 mg orally once on the first day,then 200 mg in the following 9 days. Results:After 10 days therapy, the observation group manifested a decrease in alanine amino transferase and total bilirubin(P<0. 05),an increase in albumin(P<0. 01),no significant changes in creatinine and prothrombin time(P>0. 05),and no extension in QT intervals. The total effective rates had no statistical significance between the two groups(P>0. 05). Conclusions:Oral administration of antofloxacin is effective and safe for treatment of community-acquired uncomplicated SBP.